Join to View Full Profile
311 Straight StCincinnati, OH 45219
Phone+1 513-559-2898
Fax+1 513-475-5415
Dr. Luggen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Cincinnati Medical Center/College of MedicineFellowship, Allergy and Immunology, 1980 - 1982- University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1974 - 1977
Columbia University Vagelos College of Physicians and SurgeonsClass of 1974
Certifications & Licensure
OH State Medical License 1977 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Top MD Consumers Checkbook
- Join now to see all
Clinical Trials
- Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2012 Jun 01
- Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis Start of enrollment: 2015 Feb 21
Publications & Presentations
PubMed
- 1 citationsOlokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.Eugen Feist, Roy M Fleischmann, Saeed Fatenejad, Daria Bukhanova, Sergey Grishin
Annals of the Rheumatic Diseases. 2024-10-21 - 15 citationsOlokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necro...Eugen Feist, Saeed Fatenejad, Sergey Grishin, Elena Korneva, Michael E Luggen
Annals of the Rheumatic Diseases. 2022-12-01 - 9 citationsDepression-, Pain-, and Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus.Nathalie E Chalhoub, Michael E Luggen
International Journal of Rheumatology. 2022-01-01
Press Mentions
R-pharm’s Rheumatoid Arthritis Drug, Olokizumab, Offers Significant Benefits in Phase 3 CREDO TrialMay 20th, 2021
Grant Support
- Sulfasalazine In The Treatment Of Ankylosing SpondylitisNational Center For Research Resources1990
- Early Undifferentiated Connective Tissue DiseaseNational Center For Research Resources1990
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
